Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetes
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today that empagliflozin met the primary efficacy endpoint, defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment, for all doses investigated (2.5, 10 and 25 mg) in the Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III programme in adults with type 1 diabetes. The EASE programme results were published online in Diabetes Care ahead of print and presented at the 54th EASD Annual Congress in Berlin on 4th October, 2018.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181004005237/en/
Empagliflozin is currently not approved for use in type 1 diabetes.
The EASE-2 study evaluated doses of 10 and 25 mg of empagliflozin as adjunct to insulin over 52 weeks, while the EASE-3 study evaluated doses of 2.5, 10 and 25 mg of empagliflozin as adjunct to insulin over 26 weeks. In EASE-2, placebo-corrected mean change from baseline in HbA1c at week 26 was -0.54% and -0.53% for empagliflozin 10 and 25 mg, respectively. In EASE-3 placebo-corrected mean change from baseline in HbA1c at week 26 was -0.28%, -0.45% and -0.52% for empagliflozin 2.5 and 10 and 25 mg, respectively. In addition to reduction in HbA1c, empagliflozin treatment was effective on secondary endpoints, showing reductions in weight, decreases in blood pressure, and decreases in total daily insulin dose.1
In addition, data from continuous glucose monitoring in the EASE programme indicates that patients treated with empagliflozin had improved glycaemic variability and spent more time in range, although the data for the 2.5 mg dose are limited.1
There was no increase in the risk of investigator-reported hypoglycaemic events, including severe hypoglycaemia, with empagliflozin treatment, which was a key secondary endpoint in the trials. Additionally, a reduction in patient-reported hypoglycaemic events was observed. The number of adjudicated diabetic ketoacidosis (DKA) events was comparable between empagliflozin 2.5 mg and placebo, and higher than placebo with empagliflozin 10 and 25 mg. Apart from incidence of DKA, the safety profile observed in the EASE programme was generally consistent with the previously reported safety profile of empagliflozin in adults with type 2 diabetes.1
“The goal of the EASE programme was to determine if treatment with empagliflozin could benefit people with type 1 diabetes as an adjunct to insulin,” said Bernard Zinman, M.D., Professor in the Department of Medicine, University of Toronto and Senior Scientist at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada. “Given the risk of DKA for people with type 1 diabetes, the 2.5 mg empagliflozin dose warrants consideration, as it balances glycaemic and metabolic improvements that are relevant to patients without increasing their risk of DKA or other serious adverse events.”
Based on the totality of the EASE data Boehringer Ingelheim has initiated regulatory discussions for empagliflozin as adjunct to insulin for adults with type 1 diabetes.
“The EASE programme demonstrated that empagliflozin helps patients with type 1 diabetes to remain within their target glucose range better than insulin alone,” said Dr. Jyothis George, Global Head of Clinical Development, Therapeutic Area CardioMetabolism, Boehringer Ingelheim. “There are currently no oral treatment options available for people with type 1 diabetes and these results show that empagliflozin could benefit these individuals. We look forward to working with regulatory authorities to explore whether this potential treatment can be made available to adults with type 1 diabetes.”
Jeff Emmick, M.D., Ph.D., Vice President of Product Development for Lilly Diabetes, added: “The Boehringer Ingelheim-Lilly Diabetes Alliance is committed to helping people improve the management of their diabetes, and the EASE programme is part of our broader efforts to explore treatment options that address unmet needs.”
An estimated 425 million adults worldwide have type 1 and type 2 diabetes.2 Type 2 diabetes is the most common form, accounting for around 90 percent of all cases.2 Diabetes is a chronic disease that occurs when the body does not properly produce, or use, the hormone insulin.
About the EASE Phase III programme
The EASE Phase III programme includes two multinational, double-blinded, placebo-controlled Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin as Adjunctive to inSulin thErapy in adults with type 1 diabetes (EASE), an indication for which empagliflozin is currently not approved.
evaluated 10 and 25 mg doses of empagliflozin as adjunct to insulin
versus placebo for 52 weeks3
Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment
Number of patients: 720
compared 2.5, 10 and 25 mg doses of empagliflozin as adjunct to
insulin versus placebo for 26 weeks4
Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment
Number of patients: 960
Empagliflozin is an SGLT2 inhibitor, which provides blood sugar control with additional benefits of weight loss and lowering blood pressure* in adults with type 2 diabetes. Empagliflozin is the first and only oral diabetes medicine approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. The benefit-risk profile of empagliflozin has been well-established in its approved indications. Type 1 diabetes is currently not an approved indication of empagliflozin.
* Jardiance ® is not indicated for weight loss or blood pressure reduction.
Please click on the following link for ‘Notes to Editors’ and
Dr Petra Kienle
Product Communication Manager
Phone: +49 (6132) 77 143877
Lilly Diabetes and Lilly USA
Director of Communications
Phone: +1 (317) 432-5195
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains23.10.2018 18:00 | Pressemelding
Scientists at Morinaga Milk Industry Co., Ltd. (TOKYO:2264) have long theorized that Human-Residential Bifidobacteria (HRB) are superior to non-Human-Residential Bifidobacteria (non-HRB) in promoting good health outcomes. The results of a new study strengthen the evidence for this theory, showing that infant-type HRB may be able to break down incompletely digested peptides in the infants’ gastrointestinal systems and thus contribute to their overall health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005015/en/ Fig 1. Food-derived opioid peptides are potential risk factors for human health (Graphic: Business Wire) Human-Residential Bifidobacteria for Humans Morinaga Milk has been conducting research on bifidobacteria for many years, and studies over the past decades have shown that bifidobacteria play a vital role in various aspects of human health. There are two major groups of bifidobacteria: Human-Residential Bif
myPOS Founder Christo Georgiev Announces Two Upcoming myPOS Stores in Barcelona and Paris23.10.2018 16:22 | Pressemelding
Christo Georgiev, fintech entrepreneur and founder of myPOS, has confirmed his intention to open two new flagship stores in major European cities by the end of the year. The opening is part of an initiative to bring the product closer to potential customers, giving them a hands-on experience and a live demonstration of what myPOS has to offer. The two new stores will be opened in Barcelona, Spain and Paris, France – two of the most important markets for myPOS. “Our Spanish and French customers have always placed a tremendous amount of trust in us, and we in turn have worked hard to justify it,” Georgiev says. “Opening physical locations in Barcelona and Paris is an extension of that relationship. It’s important to test a product with your own hands before you choose to trust it, and if that’s true for TVs and phones why can’t it apply to POS terminals?” The Barcelona store will open as soon as November, followed shortly by the Paris one before the end of the year. myPOS has already ope
Christo Georgiev Announces the Arrival of myPOS AppMarket23.10.2018 16:11 | Pressemelding
myPOS Europe Ltd., a leading card payments provider to small and medium-sized businesses in Europe, is introducing its own AppMarket – an innovative software platform for business applications that allows myPOS clients to find, download and use various apps for improved business performance. The development of myPOS AppMarket was driven by the necessity to meet the ever-changing business needs dictated by customer demand and behaviour. While the payment terminals myPOS offers come with a large number of innovative payments features, there are other business needs which remain uncaptured at the moment. myPOS founder Mr. Christo Georgiev says: “Individual businesses need a tailored approach when it comes to accepting payments for their services. Offering a fully customizable and complete omni-channel payments solution, which empowers businesses to stay agile, has always been in our foresight. Tapping into the familiarity of our everyday favourite device – the smartphone, pushed us even f
CNIM Presents a Rapid Version of The LCAT® Shore-to-Shore Featuring Unique Operational Capabilities23.10.2018 15:45 | Pressemelding
The L-CAT® Shore-to-shore presented by CNIM at Euronaval 2018 delivers a major increase in performance for amphibious missions. The L-CAT® Shore-to-shore has been upgrated since its launch 2 years ago. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005869/en/ CNIM's amphibious craft, the L-CAT® Shore-to-shore (Photo: CNIM) The L-CAT® Shore-to-shore is now the only vessel with the ability to transport 80 tonnes at 25 knots in conditions up to sea state 5, land in shallow water (~1m) and accommodate 42 passengers for long distance trips. Highly maneuvrable, the L-CAT® Shore-to-shore provides exceptional operational flexibility for amphibious assaults and humanitarian operations, without compromising between speed and payload. Its wide loading platform (145 m²), ability to travel up to 800 nautical miles when loaded, self-defence and communication capabilities are tactical advantages for the projection of Forces. Its spee
Exterior Plus, a Portfolio Company of H.I.G. Capital, Acquires Impactmedia23.10.2018 13:03 | Pressemelding
Exterior Plus, the out-of-home advertising platform of H.I.G. Capital, announces the acquisition of Impactmedia (the “Company”), a leading shopping mall advertising company, with over 630 million viewers in high-traffic premium locations throughout Spain. This is a major step forward in Exterior Plus’s consolidation strategy, as it aims to become the Spanish leader in out-of-home advertising with a unique, diversified and highly-competitive product portfolio, reaching very diverse audiences at a national level. Impactmedia is an experienced leader in shopping mall advertising, offering digital advertising as well as special marketing actions. The Company operates in over 90 shopping centers where it has more than 1,200 digital displays. The acquisition allows Exterior Plus to gain a strong presence near points of sale, a key value driver for advertisers. H.I.G. Capital acquired and established the Exterior Plus group in December 2015. The group currently markets more than 25,000 advert
Visa Brings a Simpler, Safer Experience to Digital Payments23.10.2018 13:00 | Pressemelding
Visa (NYSE: V) today announced a continued commitment to reducing friction and improving security in digital commerce by reiterating support of the draft EMV® Secure Remote Commerce (SRC) Specification. The draft EMV SRC Specification provides a foundation for digital transactions that gives consumers, merchants and issuers a single digital point-of-sale, resulting in a consistent, convenient and secure way to pay. EMVCo has spent the last year gathering feedback from across the payment ecosystem on the specification. Visa now encourages merchants, issuers, acquirer gateways and other interested participants to provide feedback and comment during a 45-day public comment window. Once complete, EMVCo will publish the final specification. Shoppers are increasingly migrating to websites, mobile phones and voice-activated devices, but their buying experiences are full of friction because they are required to manually enter payment details. With SRC, consumers’ digital buying experiences wil